No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATRC240517C25000
- 0.30
- 0.000.00%
15min DelayClose May 13 15:58 ET
0.30High0.15Low
0.20Open0.30Pre Close18 Volume292 Open Interest25.00Strike Price341.00Turnover116.84%IV12.59%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.30Time Value100Contract SizeAmericanOptions Type0.2071Delta0.1051Gamma74.90Leverage Ratio-0.1009Theta0.0005Rho15.51Eff Leverage0.0067Vega
Intraday
- 5D
- 1D
News
AtriCure (NASDAQ:ATRC Shareholders Incur Further Losses as Stock Declines 9.8% This Week, Taking Three-year Losses to 73%
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of AtriCure, Inc. (NASDAQ:AT
AtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price Target
AtriCure(ATRC.US) Officer Sells US$36,135 in Common Stock
$AtriCure(ATRC.US)$ Officer Noznesky Justin J sold 1,500 shares of common stock on May 1, 2024 at an average price of $24.09 for a total value of $36,135.Source: Announcement What is statement of chan
The Past Three Years for AtriCure (NASDAQ:ATRC) Investors Has Not Been Profitable
AtriCure Price Target Cut to $49.00/Share From $57.00 by Canaccord Genuity
AtriCure Price Target Cut to $49.00/Share From $57.00 by Canaccord Genuity
AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript
Comments
Insider transactions at AtriCure are not encouraging. However, insiders' share ownership suggests some alignment. Maggie Yuen's sale at a price above the current share price may not reflect insider confidence.
Investors forecast sustained strong revenue performance from AtriCure, reflected in a high P/S ratio. Shareholders currently show confidence in the company's future revenue, bolstering its shares. The high P/S ratio is deemed appropriate due to robust future revenues.
The lack of insider purchasing and ample selling in the past year could be red flags for potential investors in AtriCure. Despite high insider ownership, absence of buying is unsettling. Additionally, unspecified risks and concerns for AtriCure are noteworthy.
Read more